Apnimed, Inc. (NASDAQ:APMD – Get Free Report) major shareholder Morningside Venture Investment bought 312,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was purchased at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the completion of the purchase, the insider directly owned 7,152,713 shares of the company’s stock, valued at approximately $114,443,408. This trade represents a 4.57% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Apnimed Stock Down 3.2%
APMD opened at $27.00 on Friday. Apnimed, Inc. has a twelve month low of $16.12 and a twelve month high of $29.15.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded Apnimed to a “hold” rating in a research note on Saturday.
Apnimed Company Profile
Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.
See Also
- Five stocks we like better than Apnimed
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Apnimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed and related companies with MarketBeat.com's FREE daily email newsletter.
